ISBRG offers the SpotLight™ platform, a non‑invasive 30‑second optical biosignature screening test that captures real‑time biological signals from the body’s surface without reagents or consumables. Its proprietary Thermocline AI interprets these optical scans to generate quantitative biosignatures for indications such as early‑stage cancer, chemotherapy response, and pathogen detection, delivering immediate, cloud‑based results for point‑of‑care and large‑scale public‑health use.
Funding
Funding not disclosed
Founders
Product
Problem
Current diagnostic methods for cancer, infectious diseases, and other health conditions often require invasive sample collection, chemical reagents, and lengthy laboratory processing, limiting rapid, scalable screening and increasing costs and environmental waste.
Solution
ISBRG’s SpotLight platform delivers a non‑invasive, 30‑second optical biosignature screening test that captures real‑time biological signals from the body’s surface. Proprietary Thermocline AI interprets these optical scans to generate quantitative biosignatures for multiple indications, including early‑stage cancer detection, chemotherapy response monitoring, and pathogen identification. The system operates without reagents or consumables, providing immediate results that can be uploaded and analyzed via cloud‑based AI models. Its expandable software architecture allows new algorithms to be deployed without hardware changes, enabling rapid response to emerging health threats. By eliminating sample collection and laboratory turnaround, SpotLight offers low‑cost, environmentally friendly screening suitable for point‑of‑care and large‑scale public health deployments.
Target Audience
Primary customers are healthcare providers, diagnostic labs, and public‑health organizations seeking rapid, low‑cost, non‑invasive screening for cancer, infectious diseases, and treatment monitoring.
Features
- 30‑second, fully non‑invasive optical scan that requires no blood, saliva, or tissue samples
- Thermocline AI stack that maps optical signal changes to disease‑specific biosignatures across multiple indications
- Expandable algorithm platform (SpotLight‑C for cancer, SpotLight‑19 for pathogens) with over‑the‑air updates, no hardware modifications needed
- Real‑time result delivery via secure cloud service, eliminating days‑long lab processing
- Reagent‑free operation reduces hazardous waste and removes test expiry constraints
- Low per‑test cost designed for high‑throughput screening in inner‑city clinics and under‑staffed rural facilities